Jefferies Financial Group lowered shares of Wave Life Sciences (NASDAQ:WVE – Get Rating) from a buy rating to a hold rating in a report issued on Tuesday, The Fly reports. Jefferies Financial Group currently has $5.00 price target on the stock, down from their prior price target of $7.00.
A number of other research firms have also issued reports on WVE. StockNews.com initiated coverage on shares of Wave Life Sciences in a research note on Thursday, May 18th. They set a buy rating on the stock. HC Wainwright reissued a buy rating and set a $8.00 price target on shares of Wave Life Sciences in a research report on Thursday, March 23rd. Finally, Mizuho reissued a buy rating and set a $13.00 price target on shares of Wave Life Sciences in a research report on Friday, April 14th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Wave Life Sciences presently has a consensus rating of Moderate Buy and a consensus price target of $7.00.
Wave Life Sciences Price Performance
Wave Life Sciences stock opened at $3.76 on Tuesday. Wave Life Sciences has a 12-month low of $1.25 and a 12-month high of $7.12. The stock has a market capitalization of $369.87 million, a P/E ratio of -2.11 and a beta of -0.90. The firm’s 50-day moving average is $4.07 and its two-hundred day moving average is $4.51.
Institutional Investors Weigh In On Wave Life Sciences
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. bought a new stake in Wave Life Sciences in the third quarter worth about $3,733,000. Matisse Capital bought a new stake in Wave Life Sciences in the fourth quarter worth about $85,000. DekaBank Deutsche Girozentrale bought a new stake in Wave Life Sciences in the fourth quarter worth about $237,000. Tower Research Capital LLC TRC raised its position in Wave Life Sciences by 256.3% in the third quarter. Tower Research Capital LLC TRC now owns 9,217 shares of the company’s stock worth $34,000 after acquiring an additional 6,630 shares in the last quarter. Finally, Platinum Investment Management Ltd. raised its position in Wave Life Sciences by 32.4% in the first quarter. Platinum Investment Management Ltd. now owns 455,331 shares of the company’s stock worth $1,972,000 after acquiring an additional 111,376 shares in the last quarter. 77.18% of the stock is currently owned by institutional investors.
About Wave Life Sciences
Wave Life Sciences Ltd. is a clinical-stage genetic medicines company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, optimization, and production of novel stereopure oligonucleotides. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
- Get a free copy of the StockNews.com research report on Wave Life Sciences (WVE)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.